In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

Published Date: 20 May 2024

A 42% lower risk of tumor death, progression, or recurrence is demonstrated by the CheckMate 77T trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast cancer prevention: How nurse practitioners and physician assistants can help

2.

FDA Expands Durvalumab Label to Operable Lung Cancer

3.

ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death

4.

Mapping lifelong chronic health risks for childhood cancer survivors

5.

Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot